About: Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Novel targeted drugs for the treatment of multiple myeloma (MM) are needed to improve outcome of MM patients. Bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge MA), a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity in the 20S core of the 26S mammalian proteasome, is the first proteasome inhibitor that was approved by the US Food amd Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for patients with relapsed and refractory MM who had received at least one prior therapy and who had already undergone or are unsuitable for the transplantation of bone marrow Novel targeted drugs for the treatment of multiple myeloma (MM) are needed to improve outcome of MM patients. Bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge MA), a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity in the 20S core of the 26S mammalian proteasome, is the first proteasome inhibitor that was approved by the US Food amd Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for patients with relapsed and refractory MM who had received at least one prior therapy and who had already undergone or are unsuitable for the transplantation of bone marrow (en)
Title	Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma (en)
skos:prefLabel	Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma (en)
skos:notation	RIV/00023736:_____/09:00008561!RIV10-MZ0-00023736
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(LC06044), Z(MZ0UHKT2005)
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Fuchs, Ota
http://linked.open.../riv/druhVysledku	C - Kapitola v knize
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav hematologie a krevní transfúze
http://linked.open...dnocenehoVysledku	337252
http://linked.open...ai/riv/idVysledku	RIV/00023736:_____/09:00008561
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	multiple myeloma; proteasome; proteasome inhibitor bortezomib; apoptosis (en)
http://linked.open.../riv/klicoveSlovo	multiple myeloma proteasome apoptosis proteasome inhibitor bortezomib
http://linked.open...ontrolniKodProRIV	[D4F92B23CA96]
http://linked.open...i/riv/mistoVydani	New York
http://linked.open...i/riv/nazevZdroje	Multiple myeloma : symptoms, diagnosis and treatment
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...v/pocetStranKnihy	265 (xsd:int)
http://linked.open...cetTvurcuVysledku	1 (xsd:int)
http://linked.open...vavai/riv/projekt	Center for Experimental Hematology
http://linked.open...UplatneniVysledku	2009
http://linked.open...iv/tvurceVysledku	Fuchs, Ota
http://linked.open...n/vavai/riv/zamer	Význam molekulárně biologických vyšetření pro objasnění patogeneze a pro diagnostiku poruch krvetvorby a využití krvetvorné buňky v léčbě onemocnění krvetvorby a jiných tkání.
number of pages	48 (xsd:int)
http://purl.org/ne...btex#hasPublisher	Nova Science Publishers
https://schema.org/isbn	978-1-60876-108-1

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software